|
CLINICA CAYANGA |
||
|
|
PPI better than H2 blocker for erosive/severe GERD |
|
|
Alzheimer's
Disease Arthritis Asthma Benign Prostatic Hypertrophy Chronic Lymphocytic Leukemia Coronary Artery Disease Depression Diabetes Mellitus Dyspepsia Erectile Dysfunction Fatty Liver Gallstone Hepatitis Hypertension Lung Cancer Mesothelioma Metabolic Syndrome Obesity Pneumonia Pregnancy Prostate Cancer Sinusitis Stroke Tinnitus |
Clinical Question: For patients with known erosive esophagitis, which is the preferred maintenance therapy, proton pump inhibitors (PPIs) or H-2 antagonists? Bottom Line: The high-dose H2RA strategy is not preferred in terms of either costs or benefits. The PPI strategy appears cost effective relative to the standard-dose H2RA strategy in the following situations: when patients are significantly bothered by esophagitis and in institutional settings where the difference in drug costs between PPIs and H2RAs is small. Reference: Harris RA, Kuppermann M, Richter JE. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis. Am J Gastro 1997; 92: 2179-86 Study Design: Cost-effectiveness analysis Synopsis: Erosive esophagitis is a recurring condition for which many patients require preventive therapy. If maintenance therapy must be provided, the most cost-effective treatment strategy should be established. The authors evaluated the costs and benefits associated with three treatment strategies: 1) maintenance therapy with a proton pump inhibitor (PPI) strategy 2) maintenance therapy with a high-dose histamine-2 receptor antagonist (H2RA) strategy 3) maintenance therapy with a standard-dose H2RA. If patients experience a symptomatic recurrence on the H2RA strategies, they then receive PPI maintenance. They used a cost-effectiveness model with a 1-yr time frame; data were obtained from randomized trials of lansoprazole and ranitidine, from case series, and expert opinion. In most situations, the high-dose H2RA strategy is the most costly, yet it is less effective than the PPI strategy. Among the remaining two options, the PPI strategy is more costly and more effective than the standard-dose H2RA strategy, requiring an additional $52-688 per recurrence prevented, depending on drug acquisition costs. The greater the degree to which esophagitis decreases quality of life, the more cost effective is the PPI strategy. For example, with a $50,000 per quality-adjusted life year cost-effectiveness threshold and a market-weighted average of drug costs, the PPI strategy appears cost effective for those patients who report that symptoms of esophagitis cause greater than a 9% decrement in quality of life. |
|
|
Patient Information |
||
| Health For Life | ||
|
Medical Library |
||
|
Breaking Medical News Clinical Tools Coronary Risk Profile Dermatology Diabetes Corner Evidence-Based Medicine Free Medical Books Free Medical Journal History Taking and Physical Examination Hows on Making Diagnostic Examination Medical Journal (popular) Medical Organizations Medical Professional News Neurological and Psychiatric Problems in Clinical Practice Palm Tools Medical Notes Medical Physiology (Lecture) Medical Resources Medical Search Online Clinical Calculator Scientific Meeting |
||
| Online Sari-Sari Store | ||
Please
support Clinica Cayanga Medical Resources by purchasing gift items
at  |
||
|
Home | Introduction | Scheduling a Visit| Laboratory Work | Reaching Us | Map to our Office | About the Doctors |
||